Rapid Rebound of a Preexisting CXCR4-tropic Human Immunodeficiency Virus Variant After Allogeneic Transplantation With CCR5 Δ32 Homozygous Stem Cells

DSpace/Manakin Repository

Rapid Rebound of a Preexisting CXCR4-tropic Human Immunodeficiency Virus Variant After Allogeneic Transplantation With CCR5 Δ32 Homozygous Stem Cells
 
Verheyen, Jens; Thielen, Alexander; Lübke, Nadine; Dirks, Miriam; Widera, Marek; Dittmer, Ulf; Kordelas, Lambros; Däumer, Martin; De Jong, Dorien C.M.; Wensing, Annemarie M.J.; Kaiser, Rolf; Nijhuis, Monique; Esser, Stefan
(2019) Clinical Infectious Diseases, volume 68, issue 4, pp. 684 - 687
(Article)
Abstract
Allogeneic stem cell transplantation (alloSCT) of homozygous CCR5 δ32 stem cells once resulted in the cure of human immunodeficiency virus (HIV) infection. We have recently reported a viral breakthrough in a similar setting. Here, we demonstrate that the rapid rebound after alloSCT was related to a highly replicative CXCR4-tropic HIV ... read more
Download/Full Text
The full text of this publication is not available.
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: AlloSCT, Cure, HIV-1, Rebound, δ32 stem cells, rebound, cure, alloSCT, Delta 32 stem cells, Microbiology (medical), Infectious Diseases
DOI: https://doi.org/10.1093/cid/ciy565
ISSN: 1058-4838
Publisher: Oxford University Press
Note: Funding Information: Potential conflicts of interest. J. V. reports consultancy fees from ViiV and Janssen; grants from Janssen; payments for lectures from Janssen, Abbott, Bristol-Myers Squibb (BMS), and ViiV; and other expenses from Janssen and BMS. N. L. reports board membership with ViiV and payments for lectures from OGLMKC. M. Däumer reports board membership with Gilead, Janssen-Cilag, and Merck Sharp and Dohme (MSD). U. D. reports grants from the government agency Deutsche Forschungsgemeinschaft (DFG) (DFG TRR60). A. W. reports consultancy fees from Merck, Janssen, ViiV, Gilead, and CLJI; grants from Merck, Janssen, Gilead, ViiV, and CLJI; and other expenses from Virology Education. R. K reports a grant from BMG/MASTER-HIV-HEP; consultancy fees from MSD, ViiV, Roche, and AbbVie; and grants from DZIF-TTUHepatitis05.809. M. N. reports grants from amfAR, amfAR Research Consortium on HIV Eradication, and Aidsfonds; consultancy fees from ViiV; payment for educational presentations from Virology Education; and travel expenses from the Spanish HIV organization GeSIDA. S. E . reports board membership with AbbVie, BMS, Gilead, Janssen, MSD, and ViiV; grants from Gilead, Janssen, MSD, and ViiV; payments for lectures for AbbVie, BMS, Gilead, Janssen, MSD, and ViiV; and travel expenses from AbbVie, BMS, Gilead, Janssen, MSD, and ViiV. All other authors report no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Funding Information: Financial support. This work was supported by the Aidsfonds project (grant P-2013034 to M. N.) and the American Foundation for AIDS Research (amfAR; amfAR Research Consortium on HIV Eradication) (M. N.). Publisher Copyright: © The Author(s) 2018.
(Peer reviewed)